ICOS and breast carcinoma: To evaluate the antitumor potential of ICOS agonism, we treated EMT6 (syngeneic breast cancer model) tumor-bearing mice with an anti-mouse ICOS mAb [an Fc variant of 7E.17G9 mouse (m)IgG1].